Similar articles

• Sorafenib-induced hepatic encephalopathy.

  Marks AB, Gerard R, Fournier P, Coupe P, Gautier S. Marks AB, et al. Ann Pharmacother. 2009 Dec;43(12):2121. doi: 10.1345/aph.1M457. Epub 2009 Oct 27. Ann Pharmacother. 2009. PMID: 19861429 No abstract available.
• Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis.

  Duan F, Wang MQ, Liu FY, Wang ZJ, Song P, Wang Y. Duan F, et al. Asia Pac J Clin Oncol. 2012 Jun;8(2):156-63. doi: 10.1111/j.1743-7563.2012.01542.x. Asia Pac J Clin Oncol. 2012. PMID: 22524574
• Regression of hepatocellular carcinoma with right atrial extension after sorafenib and transarterial chemoembolization.

  Subramanian M, Singal AG, Yopp AC. Subramanian M, et al. Clin Gastroenterol Hepatol. 2012 Oct;10(10):e83-4. doi: 10.1016/j.cgh.2012.06.031. Epub 2012 Jul 17. Clin Gastroenterol Hepatol. 2012. PMID: 22813441 No abstract available.
• Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.

  Lencioni R. Lencioni R. Crit Rev Oncol Hematol. 2012 Aug;83(2):216-24. doi: 10.1016/j.critrevonc.2011.10.008. Epub 2011 Dec 3. Crit Rev Oncol Hematol. 2012. PMID: 22142656 Review.
• Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.

  O'Neil BH, Venook AP. O'Neil BH, et al. Oncologist. 2007 Dec;12(12):1425-32. doi: 10.1634/theoncologist.12-12-1425. Oncologist. 2007. PMID: 18165619 Review.